Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v64-EN Version v44-EN
Language English English
Date Updated 2019-06-19 2019-03-28
Drug Identification Number 02461412 02461412
Brand name MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
Common or Proper name EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
Company Name MYLAN PHARMACEUTICALS ULC MYLAN PHARMACEUTICALS ULC
Ingredients EFAVIRENZ TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EFAVIRENZ TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE
Strength(s) 600MG 300MG 200MG 600MG 300MG 200MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 30 BT 30 BT
ATC code J05AR J05AR
ATC description DIRECT ACTING ANTIVIRALS DIRECT ACTING ANTIVIRALS
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2019-06-11
Actual start date 2018-04-27
Estimated end date 2019-06-21 2019-04-22
Actual end date 2019-06-18
Shortage status Resolved Actual shortage
Company comments
Health Canada comments